(AOF) – LNA Santé posts group net profit of 27.6 million euros for 2023, down 6% year-on-year. The group specializing in the care of people in situations of fragility or loss of autonomy announces turnover up 5.80% to 719.8 million euros and Ebitda up 2.5 % to 143 million euros. The payment of a dividend of 0.60 euros per share will be proposed at the next general meeting on June 19, 2024, representing a distribution rate of 26%.
LNA Santé says it is targeting organic growth of 4.5% and operating turnover of more than 750 million euros in 2024, excluding external growth.
“The year 2023 was marked by a difficult situation for our sector, between multiple business and regulatory challenges, personnel tensions and persistent inflation” underline the group’s managers. “If these elements naturally influence our operations, we must underline the great resilience of LNA Santé and the adaptability demonstrated by our 9,000 professionals serving our businesses.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.